THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Growth in individuals with Saul-Wilson syndrome

Citation for published version:

Ferreira, CR, Niller, T, Duker, AL, Jackson, AP & Bober, MB 2020, 'Growth in individuals with Saul-Wilson syndrome', *The American Journal of Medical Genetics - Part A (AJMG)*.
<https://doi.org/10.1002/ajmg.a.61754>

Digital Object Identifier (DOI):

[10.1002/ajmg.a.61754](https://doi.org/10.1002/ajmg.a.61754)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

The American Journal of Medical Genetics - Part A (AJMG)

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Growth in individuals with Saul-Wilson syndrome

Journal:	<i>American Journal of Medical Genetics: Part A</i>
Manuscript ID	20-0429
Wiley - Manuscript type:	Original Article
Date Submitted by the Author:	24-Apr-2020
Complete List of Authors:	Ferreira, Carlos; NIH, NHGRI Niiler, Timothy ; Alfred I. duPont Hospital for Children, Gait Laboratory Duker, Angela; Alfred I DuPont Hospital for Children, Division of Medical Genetics Jackson, Andrew; Institute of Genetics and Molecular Medicine Bober, Michael; Alfred I. duPont Hospital Hospital for Children, Genetics
Keywords:	Saul-Wilson syndrome, primordial dwarfism, COG4, G516R
Search Terms:	

SCHOLARONE™
Manuscripts

Growth in individuals with Saul-Wilson syndrome.

Carlos R. Ferreira,¹ Tim Niiler,² Angela L. Duker,³ Andrew P. Jackson,⁴ Michael B. Bober³

¹ Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

² Gait Laboratory, Nemours/A.I. duPont Hospital for Children, Wilmington, DE, USA

³ Division of Orthogenetics, Nemours/A.I. duPont Hospital for Children, Wilmington, DE, USA

⁴ MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

Corresponding author

Carlos R. Ferreira

10 Center Drive

Building 10, Room 9N248B

Bethesda, MD 20892-1851

ABSTRACT

Saul-Wilson syndrome (SWS) is a rare autosomal recessive disorder characterized by microcephalic primordial dwarfism, spondyloepimetaphyseal dysplasia, characteristic facial findings, clubfoot, brachydactyly, bilateral cataracts, and hearing loss. Recently, recurrent mutations in *COG4*, encoding a component of the Conserved Oligomeric Golgi (COG) complex, were identified. We created detailed growth curves for stature, weight, and head circumference, as well as weight-for-length and weight velocity charts for younger children, derived from hundreds of data points obtained by retrospective chart review from 14 individuals with molecularly-confirmed SWS. In addition, we performed statistical comparisons of height-for-age model fits before and after initiation of growth hormone supplementation, and found that this therapy does not appear to influence height in individuals with SWS. We hope that these charts will represent valuable tools for clinicians, both in assessing whether SWS seems an appropriate diagnosis, as well as to monitor growth of affected individuals. In particular, we hope that our detailed growth characterization will reduce morbidity resulting from unnecessarily aggressive nutritional interventions by well-intentioned physicians trying to promote weight gain, an unrealistic goal in this genetically-determined cause of primordial dwarfism.

Key Words

Saul-Wilson syndrome; primordial dwarfism; *COG4*; G516R.

INTRODUCTION

Saul-Wilson syndrome (SWS) belongs to a group of disorders called microcephalic primordial dwarfism, characterized by pre- and postnatal growth deficiency, and microcephaly. Other than the aforementioned features of microcephalic primordial dwarfism, affected individuals also exhibit blue sclerae, large anterior fontanelle, a prominent forehead, clubfoot, brachydactyly, bilateral cataracts, rod-cone dystrophy, hearing loss, and characteristic radiographic findings (Hersh et al., 1994; R. A. Saul & Wilson, 1990; Robert A. Saul, 1982). Recently, a recurrent heterozygous amino acid substitution (p.Gly516Arg) in COG4 was identified in 14 patients (Ferreira et al., 2018). COG4 is a component of the Conserved Oligomeric Golgi (COG) complex, a multi-subunit protein complex that participates in vesicular trafficking to and from the Golgi apparatus, and is essential for the latter's structure and function (Ungar, Oka, Krieger, & Hughson, 2006). Fibroblasts from patients with Saul-Wilson syndrome demonstrate disruption of vesicular trafficking, Golgi morphology, and decorin glycosylation (Ferreira et al., 2018).

As is the case with other types of microcephalic primordial dwarfism (Bober et al., 2012), it is our experience that individuals with SWS undergo aggressive feeding regimens in early childhood, in an attempt to improve growth. This overfeeding does not, however, lead to improved growth parameters, since the cause of growth failure does not lie in undernutrition, but in the genetic nature of the condition. This phenomenon of overfeeding is partly caused by a lack of established reference curves for stature, weight, and head circumference for individuals affected with the syndrome. As growth failure represents such a prominent feature of SWS, the establishment of

normative growth curves would aid in the management of individuals with this condition, as well as in the diagnosis of patients with primordial dwarfism in general. Here, we provide an overview of growth in a unique cohort of 14 SWS patients, the largest cohort worldwide.

METHODS

Population

Data was obtained from 6 females and 8 males with molecularly-confirmed SWS, ranging in age from infancy to 39 years old. Written informed consent was obtained from all affected individuals or their parents/legal guardians. All were enrolled in at least one of the following research protocols, which were approved by their respective institutional review boards: 14-HG-0071, "Clinical and Basic Investigations into Known and Suspected Congenital Disorders of Glycosylation"; 76-HG-0238, "Diagnosis and Treatment of Patients with Inborn Errors of Metabolism or other Genetic Disorders"; "Enquiry of Participation in a Research Project about Clinical and Molecular Studies on Rare Congenital Skeletal Disorders"; or 83142, "Primordial Registry at Nemours/Alfred I. duPont Hospital for Children."

Growth calculated as standard deviations

Standard deviations (SDs) for length/height, weight, and OFC normalized for age and gender were calculated using the 2000 Centers for Disease Control and Prevention (CDC) growth charts (Kuczmarski et al., 2002). In addition, growth parameters for birth

were calculated using the revised Fenton growth charts (Fenton & Kim, 2013). Data from Roche et al. was used for calculation of head circumference Z-scores in individuals older than 36 months (Roche, Mukherjee, Guo, & Moore, 1987). A Shapiro-Wilk normality test was performed for all growth parameters at birth and at last examination (not performed at skeletal maturity given the small number of patients, n=3). Given a normal distribution, an unpaired t test was subsequently performed comparing the mean Z-scores for each growth parameter against a mean Z-score of 0 for the control population. Statistical significance was assigned to a two-tailed p-value <0.05. Analysis was performed with Prism version 6.0c (Graphpad Software Inc, La Jolla, CA).

Growth charts

The growth pattern for stature, weight, and head circumference data sets (corrected for gestational age in case of preterm birth) were modeled using locally weighted scatterplot smoothing as implemented by the loess() function in R version 3.4.0 (R Core Team, 2017). The smoothness of fit when using loess() depends on a smoothing parameter; a higher smoothing parameter considers more points in the curve and results in smoother fits to the data, while a lower smoothing parameter will more precisely fit the data locally and the best fit curve will be rougher. In this case, the best smoothing parameter was estimated using leave-one-out k-fold cross-validation in order to minimize the root mean square error of the fit and fine-tuned to each dataset via visual inspection of the final generated growth curve (Lee & Cox, 2010). Then, using 20 equally sized bins for ages between zero and three years, and 40 equally sized bins for ages between zero and 9-12.5 years (dependent on the data being modeled), loess()

was used to model the mean and `loess.sd()` from the *msir* package (Scrucca, 2011) to model the standard deviations for the variables of interest. Prediction intervals (90%, 75%, and 50%) were obtained by multiplying the standard deviations by the usual multipliers (1.64, 1.15, and 0.67, respectively). Endpoint of data modeling occurred when there were either too few data so that `loess()` failed, or when trends fit by `loess()` turned non-physical (e.g., a downturn in mean head circumference in the teenage years as a result of single individuals representing the entire group when others dropped out of the cohort). Normative reference curves were taken from CDC references (Kuczmarski et al., 2002).

Growth hormone effect

In order to ascertain the effect of human growth hormone (HGH) treatment on height, single subject linear regression models using a square root fit of subjects' height-for-age data were implemented, where pre-HGH versus post-HGH conditions were considered for each of the four subjects who received HGH therapy. These two models were then compared using analysis of variance (ANOVA). Where models were found to be significantly different, it was presumed that HGH treatment had an effect. For one subject (P6.1) who interrupted HGH therapy for approximately one year, model fits were divided so that each pre- and post-HGH condition could be compared via curve fits. Besides modeling individual subjects, models were also fit using height-for-age data from all subjects who never received HGH, and height-for-age data before initiation of HGH from subjects who eventually received this therapy. All statistics were performed using R version 3.5.2.

RESULTS

The data that supports the findings of this study (absolute growth parameters for all individuals) are available in Table S1. In total, there were 297 available data points for length/height, 416 data points for weight, and 129 data points for head circumference.

Mean standard deviation scores of individuals with SWS at birth, at last examination and at skeletal maturity are presented in table 1. Comparison of birth length and birth weight Z-scores of individuals with SWS using CDC growth charts vs. prematurity-adjusted Fenton charts did not reveal a statistical significant difference (p-values 0.11 and 0.23, respectively); this is consistent with the fact that the mean gestational age for the whole cohort was 37 weeks 2 days, thus at term. When considering weight and length/height Z-scores of SWS patients, there was strong statistical difference compared to the control population across all ages, as expected (p-values for length/height 0.002 at birth, 0.0001 at last exam, 0.0026 at skeletal maturity; p-values for weight 0.0001 at birth and at last examination, 0.0069 at skeletal maturity). For birth head circumference in the SWS cohort, there was a statistically significant difference when using CDC growth charts versus preterm-adjusted Fenton charts (p-value 0.02). Thus, we chose to compare birth head circumference of the control population against the SWS cohort using Fenton charts, which interestingly did not reveal any statistical significance (p-value 0.13). However, comparison at a later age (at last examination of head circumference, mean age 9 years 6 months) did reveal a strong statistical difference between both groups (p-value 0.0001), indicating progression to microcephaly as individuals grow older.

Correction for gestational age was not necessary for this comparison, since age at least measurement of head circumference was >2 years for all individuals born prematurely. Interestingly, while there is an absolute microcephaly present in many affected individuals during growth and at skeletal maturity, the head circumference in all individuals with SWS exceeds the height by more than 2 SD, with consequent relative macrocephaly.

Table 2 presents growth parameters expressed as absolute values. The average birth length of affected individuals measured more than two weeks behind gestational age, while the average birth weight measured more than 3 weeks behind (mean gestational age at birth for males 37 weeks 1 day, mean gestational age at birth for females 37 weeks 4 days). The average birth head circumference for females also measured more than two weeks behind gestational age, while for males it measured 1 week 6 days behind gestational age.

Figure 1 presents growth curves for stature, weight and head circumference compared to the average population. Notably, although absolute microcephaly has been traditionally considered as a cardinal feature of Saul-Wilson syndrome, patients' head circumferences vary and can overlap the lower end of the general population distribution.

Growth charts without superimposition to average population standards, which can be used for monitoring growth of individuals with SWS, are included as supplementary figures S1-S6.

Weight velocity and weight-for-length charts are useful in assessing growth and estimating nutritional status in young children, and are thus presented in Figure 2.

Four subjects received HGH supplementation, and its effect on growth was evaluated by comparing height-for-age model fits before and after initiation of therapy for each subject (Figure 3). In all cases, statistical comparisons of the model fits were not significant, with the following p-values: 0.489 for P1.1; 0.068 (first few years of HGH supplementation) and 0.071 (resumption of HGH after interruption of about one year) for P6.1; 0.411 for P9.1; and 0.052 for P10.1. Consequently, it appears that HGH does not improve height in individuals with SWS.

DISCUSSION

We provide a careful characterization of growth in individuals with SWS confirmed molecularly. We believe that this work will be important in estimating nutritional needs of individuals with SWS, by providing appropriate standards by which to base growth expectations. Additionally, and when used in conjunction with other clinical features, it will also serve as a tool in the differential diagnosis of microcephalic primordial dwarfism. Based on growth parameters alone, SWS is distinguishable from microcephalic osteodysplastic primordial dwarfism type II (MOPDII), one of the most common causes of microcephalic primordial dwarfism. The average birth length, weight, and head circumference (corrected for gestational age) in patients with MOPDII was -7.0, -3.9, and -4.6 standard deviation scores from the population mean, much smaller at birth than patients with SWS (Bober et al., 2012).

1
2
3
4 An unexpected finding in our cohort is that head circumferences of individuals with Saul-
5
6 Wilson syndrome can overlap the lower end of the general population distribution. This
7
8 may in part be explained by head circumference percentiles being overestimated with
9
10 CDC growth charts (Daymont, Hwang, Feudtner, & Rubin, 2010), with a lesser degree
11
12 of overlap seen with other head circumference growth curves. Nevertheless, Saul-
13
14 Wilson syndrome remains a microcephalic disorder for most affected individuals in
15
16 absolute measurement terms, despite the appearance of relative macrocephaly. In fact,
17
18 although head circumference was not statistically significantly different from the general
19
20 population at birth, there was significant microcephaly that developed at a later age.
21
22
23
24
25
26

27 A potential limitation of our study is that a small number of individuals (with different
28
29 number of measurements for each) were included for estimation of growth curves.
30
31 Given this limitation, the growth data was not presented as percentiles but rather as
32
33 prediction intervals, which estimate the likelihood that a future data point will fall within
34
35 this interval. To generate the provided curves, one must make the assumption that
36
37 these individuals are likely to be representative of the population of affected individuals.
38
39 Therefore, our growth charts are provided with the expectation of assisting physicians in
40
41 judging if future patients exhibit significant deviation from expected growth. In addition,
42
43 we also provide actual data points in the supplementary table, as these absolute values
44
45 might also prove useful in judging appropriate growth. While the curves provided were
46
47 based on 14 individuals, hundreds of data points were used in each model to estimate
48
49 prediction intervals. Ultimately, these curves are likely to be of diagnostic help when
50
51 evaluating a child with primordial dwarfism at the bedside, and in monitoring growth of
52
53
54
55
56
57
58
59
60

molecularly-confirmed individuals in the clinic.

In summary, we have carefully delineated the growth phenotype of SWS, creating growth charts that will be of assistance in the diagnosis of patients with primordial dwarfism in general, and in the management of individuals with SWS in particular. These charts will be useful in estimating nutritional needs of an individual with SWS by providing appropriate standards for comparison of growth parameters, and will thus likely decrease the risk of unnecessarily aggressive nutritional interventions.

ACKNOWLEDGEMENTS

This work was supported in part by the Intramural Research Program of the NHGRI. The Jackson lab is supported by the Medical Research Council, UK (MRC, MC_UU_00007/5) and the European Union's Horizon 2020 research and innovation programme ERC Advanced Grant (grant agreement no. 788093). The Primordial Registry at Nemours/Alfred I. duPont Hospital is supported by the Potentials Foundation and the Walking with Giants Foundation. We sincerely thank all the patients and their families for participating in this study.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher's website.

REFERENCES

- Bober, M. B., Niiler, T., Duker, A. L., Murray, J. E., Ketterer, T., Harley, M. E., ... Jackson, A. P. (2012). Growth in individuals with Majewski osteodysplastic primordial dwarfism type II caused by pericentrin mutations. *American Journal of Medical Genetics. Part A*, 158A(11), 2719–2725.
<https://doi.org/10.1002/ajmg.a.35447>
- Daymont, C., Hwang, W.-T., Feudtner, C., & Rubin, D. (2010). Head-circumference distribution in a large primary care network differs from CDC and WHO curves. *Pediatrics*, 126(4), e836-842. <https://doi.org/10.1542/peds.2010-0410>
- Fenton, T. R., & Kim, J. H. (2013). A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. *BMC Pediatrics*, 13, 59.
<https://doi.org/10.1186/1471-2431-13-59>
- Ferreira, C. R., Xia, Z.-J., Clément, A., Parry, D. A., Davids, M., Taylan, F., ... Freeze, H. H. (2018). A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation. *American Journal of Human Genetics*, 103(4), 553–567. <https://doi.org/10.1016/j.ajhg.2018.09.003>
- Hersh, J. H., Joyce, M. R., Spranger, J., Goatley, E. C., Lachman, R. S., Bhatt, S., & Rimoin, D. L. (1994). Microcephalic osteodysplastic dysplasia. *American Journal of Medical Genetics*, 51(3), 194–199.
- Kuczmarski, R. J., Ogden, C. L., Guo, S. S., Grummer-Strawn, L. M., Flegal, K. M., Mei, Z., ... Johnson, C. L. (2002). 2000 CDC Growth Charts for the United States: Methods and development. *Vital and Health Statistics. Series 11, Data from the National Health Survey*, (246), 1–190.

Lee, J. S., & Cox, D. D. (2010). Robust Smoothing: Smoothing Parameter Selection and Applications to Fluorescence Spectroscopy. *Computational Statistics & Data Analysis*, 54(12), 3131–3143. <https://doi.org/10.1016/j.csda.2009.08.001>

R Core Team. (2017). *R: A language and environment for statistical computing*. Vienna, Austria: R Foundation for Statistical Computing.

Roche, A. F., Mukherjee, D., Guo, S. M., & Moore, W. M. (1987). Head circumference reference data: Birth to 18 years. *Pediatrics*, 79(5), 706–712.

Saul, R. A., & Wilson, W. G. (1990). A “new” skeletal dysplasia in two unrelated boys. *American Journal of Medical Genetics*, 35(3), 388–393.

Saul, Robert A. (1982). Unknown cases. *Proceedings of the Greenwood Genetic Center*, 1(1), 102–105.

Scrucca, L. (2011). Model-based SIR for dimension reduction. *Computational Statistics & Data Analysis*, 55(11), 3010–3026. <https://doi.org/10.1016/j.csda.2011.05.006>

Ungar, D., Oka, T., Krieger, M., & Hughson, F. M. (2006). Retrograde transport on the COG railway. *Trends in Cell Biology*, 16(2), 113–120. <https://doi.org/10.1016/j.tcb.2005.12.004>

TABLES

Table 1: Growth parameters as measured by standard deviation scores compared to the general population.

* For individuals > 36 months old, head circumference Z-scores were calculated using data from Roche, Mukherjee, Guo, & Moore, 1987 (Roche, A. F., Mukherjee, D., Guo, S. M., & Moore, W. M. (1987). Head circumference reference data: Birth to 18 years.

Pediatrics, 79(5), 706–712) rounding to the nearest age for which data is available, and using a cutoff of 18 years for patients above this age.

Table 2. Growth parameters expressed as absolute values.

For adult individuals, head circumference was plotted using charts from Rollins et al. (Rollins, J. D., Collins, J. S., & Holden, K. R. (2010). United States head circumference growth reference charts: Birth to 21 years. The Journal of Pediatrics, 156(6), 907-913.e2.)

FIGURE TITLES AND LEGENDS:

Figure 1. Growth in Saul-Wilson syndrome.

(A) Length-for-age 0-3 years. (B) Height-for-age 3-12.5 years. (C) Weight-for-age 0-3 years. (D) Weight-for-age 3-12.5 years. (E) Head circumference-for-age 0-3 years. PI: Prediction interval (used for the affected population), calculated using standard deviations, gives a sense of the probability that a new data point will lie within the indicated region. CI: Confidence interval (used for the normative population), calculated using standard errors, gives a sense of the probability that the mean from a new subject will lie within the indicated region.

Figure 2. Weight-for-length and weight velocity in Saul-Wilson syndrome.

(A) Weight-for-length 0-2.5 years. (B) Weight velocity 0-3 years. PI: Prediction interval; CI: Confidence interval.

Figure 3. Effect of human growth hormone (HGH) in Saul-Wilson syndrome.

Subject Pre: height-for-age model fit for that particular subject before initiation of HGH.

Subject Post: height-for-age model fit for the same subject after initiation of HGH. No

HGH Treatment: height-for-age model fit for subjects who never received HGH

supplementation. Pre HGH Treatment: Height-for-age model fit before initiation of HGH

supplementation for subjects who eventually received this therapy. No real difference is

observed between the last two fits, or between pre-HGH and post-HGH model fits for

each individual subject.

SUPPORTING INFORMATION:

- Figure S1. Length-for-age 0-3 years.**
- Figure S2. Height-for-age 3-12.5 years.**
- Figure S3. Weight-for-age 0-3 years.**
- Figure S4. Weight-for-age 3-12.5 years.**
- Figure S5. Head circumference-for-age 0-3 years.**
- Figure S6. Head circumference-for-age 3-9 years.**

	At birth (CDC)			At birth (Fenton)			At last examination (CDC*)			At skeletal maturity (CDC)		
	Mean $\pm$ SD	Range	n	Mean $\pm$ SD	Range	n	Mean $\pm$ SD	Range	n	Mean $\pm$ SD	Range	n
Length/height (SD)	-2.4 $\pm$ 1.5	-0.4 to -5.1	12	-1.4 $\pm$ 1.5	+2.0 to -3.3	11	-6.5 $\pm$ 1.6	-4.2 to -9.8	14	-8.9 $\pm$ 0.8	-8.3 to -9.8	3
Weight (SD)	-2.4 $\pm$ 0.7	-1.2 to -3.8	14	-2.1 $\pm$ 1.0	-0.3 to -3.2	13	-4.0 $\pm$ 1.1	-1.5 to -5.6	14	-4.2 $\pm$ 0.6	-3.6 to -4.8	3
OFC (SD)	-2.0 $\pm$ 0.9	-0.8 to -3.9	11	-0.8 $\pm$ 1.4	+1.8 to -2.4	10	-1.9 $\pm$ 1.4	0.1 to -4.2	14	-3.4 $\pm$ 1.4	-2.2 to -5.0	2

	At birth				At skeletal maturity			
	Mean ± SD	Range	n	Average for (Fenton)	Mean ± SD	Range	n	Average for (CDC)
Length/height (cm)	44.1 ± 3.6	38.0 to 49.0	12	34 3/7-week neonate (males); 32 6/7-week neonate (females)	107.6 ± 1.9	106 to 109.7	3	4y 6m (male); 5y 1m (females)
Weight (kg)	2.09 ± 0.42	1.45 to 2.80	14	33 5/7-week neonate (males); 33 3/7-week neonate (females)	30.5 ± 7.4	25.3 to 39.0	3	11y 9m (male); 8y 3m (females)
OFC (cm)	31.7 ± 1.6	29.0 to 34.0	11	35 2/7-week neonate (males); 34 2/7-week neonate (females)	50.2 ± 1.7	49.0 to 51.4	2	4.5y (females*)

Figure 1. Growth in Saul-Wilson syndrome.(A) Length-for-age 0-3 years. (B) Height-for-age 3-12.5 years. (C) Weight-for-age 0-3 years. (D) Weight-for-age 3-12.5 years. (E) Head circumference-for-age 0-3 years. PI: Prediction interval (used for the affected population), calculated using standard deviations, gives a sense of the probability that a new data point will lie within the indicated region. CI: Confidence interval (used for the normative population), calculated using standard errors, gives a sense of the probability that the mean from a new subject will lie within the indicated region.

Figure 2. Weight-for-length and weight velocity in Saul-Wilson syndrome. (A) Weight-for-length 0-2.5 years. (B) Weight velocity 0-3 years. PI: Prediction interval; CI: Confidence interval.

Figure 3. Effect of human growth hormone (HGH) in Saul-Wilson syndrome. Subject Pre: height-for-age model fit for that particular subject before initiation of HGH. Subject Post: height-for-age model fit for the same subject after initiation of HGH. No HGH Treatment: height-for-age model fit for subjects who never received HGH supplementation. Pre HGH Treatment: Height-for-age model fit before initiation of HGH supplementation for subjects who eventually received this therapy. No real difference is observed between the last two fits, or between pre-HGH and post-HGH model fits for each individual subject.

1					
2					
3					
4					
5					
6					
7					
8					
9					
10					
11					
12					
13					
14					
15					
16					
17					
18					
19					
20					
21					
22					
23					
24					
25					
26					
27					
28					
29					
30					
31					
32					
33					
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46					
47					
48					
49					
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

Patient					
Age (mo)		P1.1 (male)	P2.1 (female)	P3.1 (male)	P4.1 (female)
		0	43.2	48.3	44.0
	0.4	46.0			
	0.5				
	0.6	46.5			
	0.8				
	1				
	1.3				
	1.4				
	1.6				
	2	48.5	51.4		
	2.3				
	2.5				
	3	49.5			48.0
	3.3				48.5
	3.5			48.5	
	4				
	4.5	50.8			
	4.7	52.0			
	5	54.4			
	5.5				52.0
	5.9	57.8			
	6	58.3	58.4	54.5	
	7	58.4			
	8		59.7		54.5
	9	58.5			
	10	60.2			
	11	61.3			
	12	61.5			57.5
	13	61.7			
	14	62.2		59.0	
	15	63.5	66.7		
	16	64.3			
	17				59.0
	18				
	19				
	20				
	21	67.3			
	22	67.6	69.5	63.7	
	23				63.0
	24				
	25	68.5			

1					
2					
3	26	69.8			
4	27				
5	28				
6	29	70.0	75.6		
7	30			67.0	
8	31	72.2			
9	32	73.7			66.5
10	33				
11	34				
12	35		76.0	69.9	67.5
13	36	76.5			
14	37			69.5	
15	38	76.5			
16	39	77.3			
17	40				
18	41	77.5			
19	42	77.8			
20	43	78.1			
21	45			73.0	73.0
22	46				
23	47				
24	48				
25	49				
26	50		82.3		77.0
27	51				
28	52				
29	53	80.9			
30	54				
31	55				
32	56				
33	57				
34	60				
35	61			73.8	
36	62				
37	64				
38	65		84.5		
39	66				
40	67				
41	68			83.0	
42	69				77.0
43	71				78.0
44	72				
45	73			83.6	
46	74				
47					
48					
49					
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

1				
2				
3	77			
4	78	90.0		
5	79			
6	80			
7	81		86.2	
8	84			
9	85			
10	87			
11	88			
12	89			
13	91			
14	92		88.4	
15	93			82.5
16	94			
17	95			
18	96			
19	97			
20	99			
21	100			
22	102			
23	103			
24	105			
25	107			
26	108			
27	109			
28	110	96.7		
29	114			
30	116			
31	117			
32	119			
33	120			
34	122			
35	123			
36	125			
37	127			
38	128			
39	131			
40	132	104.1		
41	133			
42	138			
43	142	108.2		
44	143			
45	147			
46	153			
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

154	
159	108.0
290	
331	
352	109.7
472	

For Peer Review

1					
2					
3					
4					
5					
6	P5.1 (male)	P5.2 (male)	P6.1 (male)	P7.1 (female)	P8.1 (male)
7	48.3	41.0	45.5		46.0
8					
9					
10					
11					
12				48.2	
13					
14					
15	50.2				
16		46.4			
17		48.3			
18		49.5			
19				52.2	
20	52.7				
21		50.6			
22					
23		52.1			
24					
25					
26	57.2				
27					
28				58.2	
29					
30					
31					
32					58.3
33					
34	60.3	58.4	56.1		60.0
35					
36					
37	61.0				61.0
38		61.0			62.5
39		61.0			62.8
40		61.6			
41	62.9				
42	64.1	64.0		62.9	
43		65.8	64.3		
44			63.9		
45					
46					
47	66.7	65.8	64.6		
48	68.6		67.1		
49	71.4	68.8		69.2	
50			67.9		
51			68.6		
52					
53	73.7	67.9			
54		67.9			
55		70.5	69.1		
56					
57	73.7				
58					
59		70.0			
60					

		69.9	74.3
		71.8	
	71.9	74.9	76.2
	72.5	74.8	75.0
		75.0	
		76.8	
80.3			
		77.5	
	76.2	79.0	
	75.0	78.8	
		80.0	
	77.0		
84.5		81.3	
	78.0		
		82.6	
		83.8	
	77.5	83.0	
84.5			
		85.1	
86.4		85.0	
		86.1	
		85.9	
	81.5		
86.4			
		87.0	85.0
		87.3	
87.6			
		88.9	
89.1		89.0	
89.5		89.5	
		91.4	

1			
2			
3			
4			
5	90.8		
6	90.7		
7	91.4		
8			
9			95.1
10		94.0	
11		94.0	
12	92.3		
13	92.7		
14			
15			
16			
17			
18		96.0	
19			
20		95.9	
21		97.4	
22			
23	93.4		
24		98.1	
25	94.0		
26	93.5		
27			
28		99.2	
29		98.8	
30			
31			
32	94.8		
33		101.8	
34		101.9	
35		102.6	
36			
37			
38		103.5	
39		104.6	
40		107.0	
41		107.0	
42			
43			
44			
45			
46		107.2	
47		108.4	
48			
49			
50		109.5	
51			
52			
53			
54			
55			
56			
57		109.5	
58			
59			
60			

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

108.0
107.3

For Peer Review

1					
2					
3					
4					
5					
6	P9.1 (female)	P10.1 (male)	P11.1 (female)	P12.1 (male)	P13.1 (female)
7	39.0	49.0	42.0		45.0
8					
9					
10			44.5		
11					
12					
13					
14				47.6	
15					
16					
17					
18					
19		56.0			
20					
21					
22					
23		56.0			53.3
24					
25					
26					
27		56.5			
28	56.0				
29					
30					
31					
32		61.0			
33					
34					
35					56.0
36					
37		62.0			
38					
39				62.3	
40					59.9
41		68.0			
42					61.6
43					62.2
44			56.0		63.5
45					
46		70.0	57.0		
47					
48	65.0				65.5
49		70.0	58.4		
50		71.5	59.5		67.3
51					
52					
53					
54	70.0			70.0	
55		72.0			
56		75.0	60.7		66.9
57			62.0		67.9
58					
59					
60					

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

		62.0		
75.5				
		62.5		
			73.7	69.7
				70.0
76.7				
77.2				
			73.7	
				72.8
80.0			76.2	70.6
81.7				73.0
83.0				
83.0				
83.4			78.7	
84.8				
88.7				
89.8				
			82.0	
94.6				
			82.5	
94.6			86.4	

1			
2			
3		96.8	
4			
5			
6			
7			
8			
9			
10			
11		98.0	
12			
13			
14			
15	101.6	98.0	
16			91.0
17			
18			
19			
20			
21	102.9	98.0	
22			
23			
24			
25			
26			
27			
28		101.0	
29			
30	105.5		96.0
31			
32			
33		100.9	
34			
35			
36			
37		102.8	
38	109.0		
39			
40		102.7	
41			
42			
43			
44	112.5	103.4	
45			98.4
46		104.5	
47	113.0		
48			
49		105.0	
50			
51			
52			
53	115.2	106.9	
54	116.8		
55	117.8		
56			
57			
58	118.9		
59	120.1		
60			

120.5

106.0

For Peer Review

1	
2	
3	
4	
5	
6	Comment
7	
8	
9	12 do
10	15 do
11	20 do
12	23 do
13	
14	
15	40 do
16	42 do
17	49 do
18	
19	
20	68 do
21	77 do
22	
23	
24	100 do
25	106 do
26	
27	
28	136-141 do
29	143 do
30	
31	
32	164-169 do
33	178 do
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patient					
Age (mo)		P1.1 (male)	P2.1 (female)	P3.1 (male)	P4.1 (female)
0		2.2	2.5	1.9	1.5
0.4		2.1			
0.5					
0.6		2.3			
0.8					
1		2.6			
1.3		2.8			
1.4					
1.6					
2		2.8	2.8		
2.3					
2.5					
2.6		3.3			
3		3.4			2.7
3.3					2.9
3.5				3.2	
3.7		3.6			
4		3.8			
4.5		4.0			
4.7		3.9			
5		4.3			3.3
5.3					
5.5					
5.8		4.5			
6		4.8	3.8	4.2	
7		4.6			
8			4.3		3.7
9		5.1			
10		5.0			
11		5.2			
12		5.2			4.0
13		5.3			
14		5.7		5.0	
15		5.7	6.0		
16		6.0			
17					4.5
18					
19					
20		6.2			
21		6.3			
22		6.5	6.9	5.5	

1					
2					
3	23				5.2
4	24	6.8			
5	25	7.1			
6	26	7.0			
7	27				
8	28				
9	29	7.7	6.5		
10	30	7.5		6.6	
11	31	7.6			
12	32	7.3			6.0
13	33				
14	34	7.3			
15	35		7.3	6.8	6.2
16	36	8.1			
17	37			7.0	
18	38	8.3			
19	39	8.6			
20	40				
21	41	8.7			
22	42	9.4			
23	43	9.0			
24	44				
25	45			7.5	7.1
26	46				
27	47				
28	48				
29	49				
30	50		8.5		7.8
31	51				
32	52				
33	53	9.7			
34	54				
35	55				
36	56				
37	57				
38	58				
39	59				
40	60				
41	61			7.5	
42	64				
43	65		9.5		
44	66				
45	67				
46	68			9.5	
47					
48					
49					
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

1			
2			
3	69		7.8
4	71		8.1
5	72		
6	73	10.0	
7	74		
8	75		
9	76		
10	77		
11	78	10.8	
12	79		
13	80		
14	81	9.8	
15	82		
16	83		
17	84		
18	85		
19	87		
20	88		
21	89		
22	90		9.6
23	92	10.1	
24	93		9.5
25	94		
26	95		
27	96		
28	97		
29	98		
30	99		
31	100		
32	102		
33	103		
34	105		
35	107		
36	108		
37	109		
38	110	12.1	
39	113		
40	114		
41	116		
42	117		
43	119		
44	120		
45	121		
46	122		
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

1		
2		
3	123	
4	125	
5	126	
6	127	
7	128	
8	129	
9	131	
10	132	15.4
11	133	
12	137	
13	138	
14	141	
15	142	20.2
16	143	
17	147	
18	149	
19	153	
20	154	
21	159	20.0
22	165	
23	172	20.4
24	205	22.7
25	233	22.7
26	262	24.9
27	290	
28	298	24.5
29	331	
30	352	25.3
31	472	
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

P5.1 (male)	P5.2 (male)	P6.1 (male)	P7.1 (female)	P8.1 (male)
2.2	1.8	2.2	2.0	2.8
2.5				
			2.2	
3.3	2.8			
	3.0			
	3.2		3.0	
3.8	3.5			
3.8	4.0			
4.2	4.1			
4.3	4.3		3.8	
	4.5			
4.6				4.8
	4.6			
4.9				4.9
	4.8			
5.0	4.9	4.3		5.0
5.1	5.3			5.3
5.3	5.4			5.6
5.4	5.2			5.7
5.1	5.8			5.7
6.0	5.9			
6.4	6.2	5.8	5.2	
7.4	6.4	5.8		
7.6	6.4	6.0		
	6.7			
8.6	7.0	6.3		
9.0	6.8	6.5		
9.5	7.0	6.6	6.8	
	7.3	6.7		
	7.2	6.9		
11.5	7.3			
11.3	7.3			

1				
2				
3		7.4	7.5	
4		7.4		
5	11.2			
6				
7	11.9	7.7	7.6	7.3
8	12.0	7.5	7.7	
9	12.4	8.2	8.2	
10	11.5	8.1	7.9	8.0
11	12.2	8.2	8.3	8.3
12		8.3		
13		8.4		
14	11.8	8.6	8.4	
15			8.7	
16	12.1		9.1	
17		8.6		
18			8.7	
19		8.8	9.4	
20	11.8	9.0	9.1	
21	11.7	9.1	9.1	
22		9.3		
23	11.6			
24		9.2		
25		9.5		
26	12.7		9.8	
27	11.8	9.7		
28				
29	12.4		10.0	
30			10.0	
31		9.8	10.1	
32	12.5	10.0		
33		10.0	10.9	
34	12.1		10.4	
35	12.2		10.4	
36	12.2		10.7	
37	12.7	10.3		
38			10.6	
39	12.7			
40	12.5	10.7		10.7
41			10.2	
42	12.7		11.0	
43	12.3		10.5	
44	12.7			
45	12.9		10.4	
46	12.9		10.7	
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1			
2			
3	13.2	10.4	
4		10.9	
5			
6	13.0		
7			
8			
9			
10		11.6	
11	13.2		
12	13.2		
13	12.7		
14	13.9		
15	14.1	12.2	
16			11.9
17			
18	13.8		
19	14.1		
20	14.5	13.0	
21	15.0	13.4	
22	15.2	14.8	
23	14.6		
24	14.5		
25	14.1	13.6	
26		13.4	
27		14.7	
28	14.5	15.0	
29	14.5		
30		15.0	
31		15.2	
32	14.2		
33	13.8		
34		15.3	
35		15.1	
36	14.7		
37	14.5		
38	14.5	17.2	
39		17.0	
40	14.9	17.3	
41		18.1	
42			
43		19.3	
44		19.6	
45		20.8	
46		21.3	
47		20.7	
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

1		
2		
3		
4		
5	21.9	
6	22.3	
7	22.8	
8		
9		
10	22.7	
11	23.7	
12		
13		
14		
15	24.8	
16		
17		
18	26.6	
19		
20	23.7	
21		
22		
23	28.4	
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		23.8
35		
36		
37		30.2
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

P9.1 (female)	P10.1 (male)	P11.1 (female)	P12.1 (male)	P13.1 (female)	Comment
2.1	2.8	1.8	1.5	2.2	
				2.2	12 do
		2.1			15 do
					20 do
					23 do
			2.4	3.0	
					40 do
					42 do
					49 do
	3.8			3.7	
					68 do
					77 do
					81 do
	4.2			3.6	
					100 do
					106 do
					112 do
	3.8				
4.5					136-141 do
		3.8		4.0	143-147 do
				4.1	
					161 do
	4.6				164-169 do
					171-178 do
				4.3	
				4.3	
	6.0				
		4.3	4.7	5.0	
		4.8		5.1	
	7.4				
		4.4		5.2	
		4.8		5.5	
				5.7	
	8.2	4.7			
6.5		4.9		5.9	
	8.5	5.0			
	8.8	5.2		6.3	
		5.0			
7.3			6.5	6.3	
	8.9				

1				
2				
3	9.1	5.7		6.7
4		5.4		
5				
6				7.1
7		5.8		
8	9.2			
9		6.1		
10			7.0	
11				
12				7.1
13	10.3			
14				
15				
16	10.6			
17			7.7	
18				
19				
20				7.6
21	11.0		8.3	
22				
23				
24				
25	11.6			7.7
26				8.1
27				
28				
29	10.9			
30				
31				
32				
33	10.3			
34	11.3			
35				
36				
37	12.0		8.6	
38				
39				
40				
41	11.6			
42				
43				
44				
45				
46				
47				
48	13.1			
49				
50				
51				
52				
53	13.3			
54	13.3			
55				
56				
57				
58			10.5	
59				
60				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	13.0	
	15.0	12.6
	16.0	
	15.6	
	15.0	
16.5	14.8	
19.1	15.3	
	15.3	
22.0		
	15.4	
	16.2	
24.6		
	15.6	
26.6	15.9	

1			
2			
3			19.5
4			
5		16.2	
6			
7	28.0		
8		16.0	
9			
10			
11			
12			
13			
14	30.5	17.3	
15			
16	31.6		
17			
18			
19	33.8		
20			
21			
22	36.7		
23			
24	36.8		
25	37.1		
26			
27			
28	37.6		
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			39.0
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

1					
2					
3					
4					
5					
6					
7					
8					
9					
10					
11					
12					
13					
14					
15					
16					
17					
18					
19					
20					
21					
22					
23					
24					
25					
26					
27					
28					
29					
30					
31					
32					
33					
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46					
47					
48					
49					
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

Patient					
Age (mo)		P1.1 (male)	P2.1 (female)	P3.1 (male)	P4.1 (female)
0			31.8	30.0	29.0
0.5					
0.6		32.7			
0.8					
1					
2			32.3		
3		38.0			
3.3					36.0
3.5				36.5	
4					
4.5					
5					
5.5					39.0
6		42.1	39.0	40.0	
7		42.9			
8			40.8		41.5
10		45.0			43.0
11					
12					
13		45.1			
14		45.5		42.5	
15			43.6		
16		46.0			
17					44.5
18					
21					
22			44.5	43.8	
23					45.5
24		47.0			
25		47.5			
26					
29			44.8		
30				45.2	
31		48.2			
32		48.8			46.5
33					
35			45.6		46.5
37				45.8	
39					
45				46.0	47.5
46					

1			
2			
3	49		
4	50		48.0
5	54		
6	57		
7	61		
8	62		
9	64		
10	65	45.6	
11	69		48.0
12	71		48.0
13	78	46.0	
14	79		
15	81		46.5
16	88		
17	92		47.1
18	93		48.5
19	95		
20	96		
21	97		
22	102		
23	105		
24	107		
25	108		
26	110	46.6	
27	114		
28	116		
29	120		
30	123		
31	132	47.0	
32	172	47.8	
33	205	47.5	
34	233	48.5	
35	262	49.5	
36	290		
37	327		
38	352	49.0	
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

P5.1 (male)	P5.2 (male)	P6.1 (male)	P7.1 (female)	P8.1 (male)
33.0	31.5	30.5		33.5
			31.5	
			35.0	
			38.5	
				43.4
45.5				44.0
				45.2
				46.0
			43.5	
		45.9		
			46.0	
			46.6	
	50.3		48.0	
	50.7			
	51.2			

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

51.6

49.0

50.5

50.6

49.2

50.7

50.6

50.0

50.7

50.0

51.0

51.4

For Peer Review

P9.1 (female)	P10.1 (male)	P11.1 (female)	P12.1 (male)	P13.1 (female)	Comment
	34.0			32.0	
		32.0			15 do
				33.0	20 do
					23 do
				35.6	
	38.0			37.5	
					100 do
					106 do
	38.0				139 do
				40.0	
	42.5				164-169 do
				41.0	
				42.2	
	43.5				
				44.0	
	45.2				
		42.1			
		42.0		45.1	
		43.4			
				46.0	
	47.0	43.5			
		43.5			
		43.9		46.7	
	47.2	44.5			
				47.0	
				47.7	
				47.8	
	48.0				
				48.5	

1			
2			
3			48.0
4			
5			
6	49.5		
7			
8			
9			48.7
10			
11	49.2		
12			
13			
14			
15			
16			
17			
18	50.0		
19			
20			
21			
22			
23			
24	50.4		
25			
26			
27			
28	50.4		
29			49.8
30			
31			
32	50.3		
33			
34			
35	49.7		
36	51.0		
37			
38			50.0
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60